New treatment for advanced non-small-cell lung cancer using a virus and chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, open-label, randomized study evaluates the efficacy and safety of Olvimulogene Nanivacirepvec, an oncolytic virus, combined with platinum-doublet chemotherapy and a physician's choice of immune checkpoint inhibitor, compared to docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). Participants must have experienced disease progression while on prior treatments and have measurable tumors. The study aims to determine if this combination can enhance immune activation and resensitize tumors to chemotherapy. It includes patients with both squamous and non-squamous NSCLC without known targetable genetic alterations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female 18 years or older.
* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.
* Have histologically or cytologically confirmed advanced or metastatic NSCLC.
* Histologically confirmed Stage III or IV squamous or nonsquamous \[American Joint Committee on Cancer (AJCC) 8th edition\].
* Received at least 2 cycles and maximum of 6 cycles of front-line platinum-based chemotherapy with ICI-based therapy, regardless of PD-L1 expression.
* Reached first disease progression by radiological assessment while receiving front-line or maintenance ICI.
* At least one measurable target tumor lesion anywhere except the brain per RECIST 1.1 by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan.
* Have adequate renal, hepatic, bone marrow function as well as adequate coagulation tests \[International Normalized Ratio (INR)\] and adequate immune function by lymphocyte count.
* Women of child-bearing potential must have a negative serum pregnancy test prior to initiating study dosing.
* Be willing and able to comply with scheduled visits, the treatment plan, imaging and laboratory tests.

Exclusion Criteria:

* Active and untreated urinary tract infection, pneumonia, or other systemic infections.
* Current symptomatic central nervous system (CNS) metastasis.
* Any uncontrolled systemic disease, condition or comorbidity that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
* Persistent toxicities \[Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3\] caused by previous anticancer therapy; alopecia and vitiligo are excluded toxicities.
* Required the use of additional immunosuppression other than corticosteroids for the management of an adverse event or have experienced recurrence of an adverse event if re-challenged, or currently require maintenance doses of \>10 mg prednisone or equivalent per day.
* Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, tecovirimat, or other agents with known anti-vaccinia activities).
* Underwent major surgery within 4 weeks, or have insufficient recovery from surgical-related trauma or wound healing, prior to the planned first dose of treatment in either Arm.
* Have received prior virus-based gene therapy or therapy with cytolytic virus of any type.
* Vaccination against smallpox or monkeypox within 1 year of study therapy.
* Any non-oncology vaccine therapy used for prevention of infectious diseases, such as seasonal (influenza) vaccinations, corona virus disease (COVID) vaccination or other vaccines, within 2 weeks of the planned first dose of study drug.
* Clinically significant skin disease as assessed by the Investigator (e.g., severe eczema, psoriasis, or any unresolved skin injury or ulcer).
* Known hypersensitivity to carboplatin, cisplatin, paclitaxel or nab-paclitaxel, docetaxel, or any of the constituents of Olvi-Vec (i.e., gentamicin).
* Had severe hypersensitivity (CTCAE Grade ≥ 3) to ICI and/or any of its excipients previously.
* Dementia or altered mental status that would prohibit informed consent, and/or psychiatric illness/social situations that might interfere or limit compliance with study requirements.

Where it's running

• Pioneer Research Center, LLC
  Bullhead City, Arizona, United States Recruiting
• Clermont Oncology Center
  Clermont, Florida, United States Recruiting
• Oncology & Hematology Associates of West Broward
  Coral Springs, Florida, United States Recruiting
• Helios Clinical Research
  Fort Lauderdale, Florida, United States Recruiting
• Bioresearch Partner
  Hialeah, Florida, United States Recruiting
• University of Miami - Sylvester Comprehensive Cancer Center
  Miami, Florida, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pulmonary rehabilitation for people who survived advanced non-small cell lung cancer

  This research will try an eight-week pulmonary rehabilitation program to see if it helps people with advanced non-small cell lung cancer breathe easier and have more energy.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07104630

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• First-Line Ipilimumab, Nivolumab, and IL-15 Superagonist in Advanced or Recurrent NSCLC

  A phase Ib/II study tests whether adding nogapendekin alfa inbakicept to nivolumab and ipilimumab helps people with stage IV or recurrent non-small cell lung cancer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07355205

• Proteomic-guided, risk-adapted therapy for advanced non-small cell lung cancer

  This trial tests whether using a proteomic test plus a toxicity risk tool to pick immune checkpoint inhibitor–based treatment can improve 12-month progression-free survival for people with previously untreated advanced non-small cell lung cancer.

  Recruiting at 4 sites Phase 2 University of California, Davis · Chico, California and 3 other locations · NCT07250477

• Combining JAB-21822 and JAB-3312 for advanced lung cancer with KRAS mutation

  This study is testing if a new combination of JAB-21822 and JAB-3312 can help people with advanced lung cancer that has a specific KRAS mutation do better than the usual treatment.

  Recruiting at 6 sites Phase 3 Allist Pharmaceuticals, Inc. · Hefei, Anhui and 36 other locations · NCT06416410

• Personalized treatment for early stage non-small cell lung cancer using blood tests

  This study is testing if a blood test for cancer DNA can help find leftover cancer in people with early stage lung cancer after treatment, and if giving them a specific immunotherapy can help reduce it.

  Recruiting Phase 2 Stanford University · Stanford, California · NCT04585477

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.